Sesen Bio is now Carisma Therapeutics, self-described as a biopharmaceutical company focused on improving patient outcomes.

Sesen Bio

Domain Not Resolving

Microsoft Exchange Online

Apache

Office 365 Mail

Microsoft Azure DNS

Common Name Invalid

403 Error

American Express

Network Solutions DNS

Vice President, Assistant General Counsel

Amy Ponpipom

Information Technology

Glen MacDonald

Chief Development Officer

Minori Rosales

Chief Financial Officer

Monica Forbes

President and CEO

Tom Cannell

Vice President, Corporate Strategy & Investor Relations

Erin Clark

Vice President, Business Development and Alliance Management

Omar Rifi

Senior Director, Medical Affairs

Diane Dell'Armo

Senior Director

Dominika Kowalski

Director of Accounting, Assistant Controller

Jacqueline Fayeghi

Kenji Harada

Daniel Lynch

Cary Pfeffer

Jane Pritchett Henderson

Chief Technology Officer

Casey Weaver

Co-Founder

Flagship Pioneering Portfolio Companies

United States Health Care Acquired Companies

Medical Device Companies With Fewer Than 100 Employees (Top 10K)

Northeastern US Acquired Companies With Less Than $500M in Revenue

Sesen Bio is a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents based on their Targeted Protein Therapeutics (TPTs) platform. Their TPTs genetically combine targeting antibody fragments with cytotoxic protein payloads to create a single fusion protein through Eleven's proprietary one-step manufacturing process.

Post-IPO Equity - Sesen Bio

JAFCO

Series A - Sesen Bio

Flagship Pioneering

Third Rock Ventures

Cambridge

Massachusetts

United States

North America

Sesen Bio Stockholders Approve Merger with Carisma Therapeutics

Latest terms of Sesen Bio and Carisma merger appear to pass muster

Sesen Bio, Carisma Therapeutics amend merger deal after reaching agreement with investor group

Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger

Sesen Bio pushes back after investor group attacks merger as ‘illogical’

Carisma Therapeutics and Sesen Bio merger draws opposition from large shareholder

Why The Sesen Bio (SESN) Stock Surged 30.45% After Hours

Stocks to Watch: Sesen Bio, Model Performance Acquisition, Heidrick & Struggles

SESN Investors Have Opportunity to Lead Sesen Bio, Inc. Securities Fraud Lawsuit

A locally administered targeted fusion protein for the treatment of BCG-unresponsive non-muscle invasive bladder cancer.

An anti-PSMA humabody-deBouganin fusion protein designed for tumor cell killing and overcoming drug resistance.

India

Asia

Morocco

Africa

Estonia

Europe

HTML5

Modernizr

GoDaddy Premium DNS

Google Tag Manager

Google Analytics

jQuery

Google Fonts

Adobe Fonts

Wordpress

Microsoft Outlook

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 17, 2024 3:25 PM	d9c26d2b
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 17, 2024 3:25 PM	c1555bff
crunchbase trigger	general	Nov 17, 2024 3:25 PM	8cde7bd9
crunchbase profile	general	Nov 17, 2024 3:43 PM	e77848e6
li profile	general	Nov 17, 2024 3:25 PM	33694a26
translate crunchbase fundingrounds	general	Nov 17, 2024 4:18 PM	96a79c33
peers	general	Nov 17, 2024 3:25 PM	ff375569
news basic	general	Nov 17, 2024 3:25 PM	f083c905
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:SESENBIO

Sesen Bio